Effects of leukotriene D4 nasal challenge on bronchial responsiveness and inflammation in asthmatic patients with allergic rhinitis

Zhu, Zheng; Xie, Yanqing; Guan, Weijun; Gao, Yi; Huang, Rongquan; Xia, Shu; Jian, Wenhua; Liang, Zhiyu; Zheng, Jinping

doi:10.21037/jtd.2017.02.36

Cited by 4 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, purinergic receptors and GPR17 have also been suggested as possible receptors for cysteinyl leukotrienes, http:// links.lww.com/PRS/F125.] Leukotrienes participate in inflammatory responses, and their overproduction is associated with asthma, atopic dermatitis, cardiovascular disease, and cancer, [13][14][15][16][17][18][19][20][21][22][23][24][25] but they also play roles in tissue homeostasis. 26,27 Members of the 5-lipoxygenase pathway are expressed in various immune cells, such as neutrophils, 28 macrophages, 29 lymphocytes, 30 and dendritic cells, 31 but also in nonimmune cells such as neuronal cells and endothelial cells.…”

Section: Ementioning

confidence: 99%

Montelukast, an Antagonist of Cysteinyl Leukotriene Signaling, Impairs Burn Wound Healing

Nguyen

Bagood

Wang

et al. 2022

Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

In the United States, over 30,000 patients are hospitalized annually because of burn injuries. 1 These injuries are often slow to heal, leading to lengthy hospitalization time, increased health care costs, and lower quality of life. Burnassociated impaired healing is linked to deregulated inflammation at the site of the injury driven by skin-resident and infiltrating peripheral immune cells. [2][3][4] Although certain inflammatory responses impair healing, 5-8 others promote tissue repair and reconstruction. [7][8][9][10][11][12] Thus, defining prorepair pathways associated with inflammation is a crucial step for the development of successful therapeutic strategies.Leukotrienes are short-lived lipid mediators derived from the conversion of arachidonic acid by 5-lipoxygenase and consist of leukotriene B 4 and the cysteinyl leukotrienes: leukotriene C 4 , leukotriene D 4 , and leukotriene E 4 . 13,14 [See Figure, Supplemental Digital Content 1, which shows the 5-lipoxygenase (5-LO) pathway. A variety of stimuli can induce the release of arachidonic acid from membrane phospholipids by cytosolic phospholipase A2 (cPLA2; gene name, Pla2g4a). 5-Lipoxygenase (gene name, Alox5), together with 5-lipoxygenase activating protein (FLAP; gene name, Alox5ap), converts free arachidonic acid to form the unstable intermediate leukotriene A4 (LTA4). Leukotriene A4 can be either hydrolyzed by leukotriene A4 hydrolase (LTA4H; gene name, Lta4h) to form leukotriene B4 (LTB4) or conjugated to reduced glutathione by leukotriene Background: Burns are severe injuries often associated with impaired wound healing. Impaired healing is caused by multiple factors, including dysregulated inflammatory responses at the wound site. Interestingly, montelukast, an antagonist for cysteinyl leukotrienes and U.S. Food and Drug Administration approved for treatment of asthma and allergy, was previously shown to enhance healing in excision wounds and to modulate local inflammation. Methods: In this study, the authors examined the effect of montelukast on wound healing in a mouse model of scald burn injury. Burn wound tissues isolated from montelukast-and vehicle-treated mice at various times after burn injury were analyzed for wound areas (n = 34 to 36), reepithelialization (n = 14), inflammation (n = 8 to 9), and immune cell infiltration (n = 3 to 6) and proliferation (n = 7 to 8). Results: In contrast to previously described beneficial effects in excision wounds, this study shows that montelukast delays burn wound healing by impairing the proliferation of keratinocytes and endothelial cells. This occurs largely independently of inflammatory responses at the wound site, suggesting that montelukast impairs specifically the proliferative phase of wound healing in burns. Wound healing rates in mice in which leukotrienes are not produced were not affected by montelukast. Conclusion: Montelukast delays wound healing mainly by reducing the proliferation of local cells after burn injury. (Plast. Reconstr. Surg. 150: 92e, 2022.) Clinical Relevance Statement: Al...

show abstract

Section: Ementioning

confidence: 99%

Montelukast, an Antagonist of Cysteinyl Leukotriene Signaling, Impairs Burn Wound Healing

Nguyen

Bagood

Wang

et al. 2022

Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

show abstract

“…Nasal lavage was performed by an experienced technician as previously described (19). The subject sat upright with head poised forward, sterile saline solution (10 mL, room temperature) was infused into both nostrils for seven times by using a syringe with a sponge adapter.…”

Section: Nasal Lavagementioning

confidence: 99%

Response of upper and lower airway inflammation to bronchial challenge with house dust mite in Chinese asthmatics: a pilot study

Zhu¹,

Wang²,

Xie³

et al. 2021

J Thorac Dis

Self Cite

View full text Add to dashboard Cite

Background: Allergen nasal challenge can induce increase of eosinophils in sputum, but report about eosinophilic inflammation in upper airway after allergen bronchial challenge in Chinese asthmatics was rare. The article aims to evaluate response of upper and lower airways to house dust mite (HDM) allergen bronchial challenge. Methods: HDM allergen bronchial challenge was carried out in asthmatic patients with allergic rhinitis (AR). Bronchial methacholine challenge and blood test were performed before and at 24 hours after allergen challenge. Nasal lavage and induced sputum for differential cells count and fractional exhaled nitric oxide (FeNO) measurement were performed before, 7 and 24 hours after allergen challenge.Results: Eighteen asthmatic patients with AR underwent HDM allergen bronchial challenge with no serious adverse events reported. Fifteen patients showed dual asthmatic response (DAR), while 2 patients showed early (EAR) and 1 late asthmatic response (LAR) only. At 24 hours after allergen bronchial challenge testing, average PC 20 FEV 1 to methacholine significantly decreased (1.58 to 0.81 mg/mL, P=0.03), while both FeNO and the percentage of eosinophils in blood and sputum were significantly increased [52.0 (54.0) to 69.0 (56.0) ppb, P=0.01; 4.82% to 6.91%, P<0.001; 20.70% to 27.86%, P=0.03, respectively], but with no significant differences found in the percentage of eosinophils in nasal lavage (39.36% to 38.58%, P=0.89). However, at 7 hours after allergen challenge, the eosinophils in sputum were significant increased to 40.45% (P<0.001), but there was an increase (39.36% to 48.07%) with no statistical difference (P=0.167) found in nasal lavage. Conclusions: HDM allergen bronchial challenge induced different response of airway inflammation in upper and lower airways.

show abstract

“…Angiotensin is a peptide with strong vasoconstrictive effect, which is mainly involved in the regulation of human blood pressure [7]. Leukotriene D4 [8] is an important inflammatory mediator in human body, which participates in the process of chronic inflammation and oxidative stress injury in the brain. Hexadecanedioic acid [9] is an intermediate substance involved in fatty acid metabolism.…”

Section: Biological Interpretation Of Metabolic Markersmentioning

confidence: 99%

“…The pathways of 54 metabolites from the high dose SCPE callback obtained in the previous step were analyzed. Firstly, the metabolic pathways were annotated based on KEGG and HMDB database, and then the MetaboAnalyst [8] online software analysis tool was used to set the input format of metabolites to Compoundname/HMDBID/KEGG ID, and set Impact greater than 0.1 as the screening criteria for the main metabolic pathways. After analysis, four main metabolic pathways were obtained (Figure 19 and Table 10): Phenylalanine metabolism; Alanine, aspartate and glutamate metabolism; Cysteine and methionine metabolism; D-Glutamine and D-glutamate metabolism.…”

Section: Screening and Pathway Analysis Of Biomarkers Of High Dose Scmentioning

confidence: 99%

Metabolomics Study on Improvement of Mild Cognitive Impairment by SCPE: a UPLC-Q/TOF-MS Mass Spectrometric Study

Hou

Sun

Wei

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Mild Cognitive Impairment (MCI) is a common and easilyneglected neurological disease in clinic. Aging is the main cause of the disease,but its exact pathogenesis is not yet clear. Sagacious Confucius' PillowElixir(SCPE) is a classic medicine for the treatment of amnesia in traditionalChinese medicine.The aim of this study was to prove the stability and reliabilityof SAMP8 mice as MCI model, and to nd potential biomarkers for thetransformation of mild cognitive impairment to dementia, so as to reveal thepathogenesis of mild cognitive impairment and the mechanism of SCPE at thewhole animal level.Methods: Senescence-accelerated P8 (SAMP8) mice were selected as the modelof MCI. Based on UHPLC/Q-TOF-MS platform, the eect of SCPE on MCI micewas evaluated by metabolomics to screen and identify brain tissue biomarkers andpathways of MCI. T test of SPSS 22.0 software and meta-analysis software wereused for univariate and multivariate analysis to screen and identify the biomarkersand pathways of brain tissue with mild cognitive impairment; SPSS 22.0statistical software was used to conduct t-test on the total ionic strengthcorresponding to the dierent metabolites in each group, and to clarify thechange mechanism of biomarkers and pathways in dierent doses of SCPE.Results: From the point of view of brain metabolomics, 84 MCI-relatedbiomarkers and 8 metabolic pathways were identied. It was found that dierentdoses of SCPE could call back 36 same metabolic markers and 3 commonmetabolic pathways.And with the increase of dose, the number of SCPE callbackmetabolic markers gradually increased(LD:40; MD:48; HD:54), and the types ofmain metabolic pathways also changed to a certain extent (the biosynthesis ofvaline, leucine and isoleucine in low dose changed to cysteine and methioninemetabolic pathway in middle and high dose),which may be related to the eectof aminoacyl tRNA.Conclusions: The stability and reliability of MCI model, and the eectiveness ofSCPE in the treatment of MCI were clared. Compared three dierent dosegroups, the high dose SCPE group has more advantages.

show abstract

Effects of leukotriene D4 nasal challenge on bronchial responsiveness and inflammation in asthmatic patients with allergic rhinitis

Cited by 4 publications

References 26 publications

Montelukast, an Antagonist of Cysteinyl Leukotriene Signaling, Impairs Burn Wound Healing

Montelukast, an Antagonist of Cysteinyl Leukotriene Signaling, Impairs Burn Wound Healing

Response of upper and lower airway inflammation to bronchial challenge with house dust mite in Chinese asthmatics: a pilot study

Metabolomics Study on Improvement of Mild Cognitive Impairment by SCPE: a UPLC-Q/TOF-MS Mass Spectrometric Study

Contact Info

Product

Resources

About